Introduction
============

*Staphylococcus aureus* causes a broad variety of illnesses in human beings from minor skin soft-tissue infections to intense infections such as septicemia, toxic shock syndrome, endocarditis and severe pneumonia \[[@b1-ophrp-10-0025]\]. At the beginning of 1961, the increasing rate of methicillin-resistant *S. aureus* (MRSA), and its distribution in therapeutic centers and the community appeared a noteworthy problem worldwide \[[@b2-ophrp-10-0025]\]. There are many drugs appropriate for the treatment of Staphylococcal infection such as aminoglycosides, tetracyclines, fluoroquinolones, macrolide (erythromycin), lincosamide (clindamycin), and vancomycin, linezolid, and daptomycin, but they swiftly lose their healing potential because of the capacity of bacteria to progress towards effective mechanisms to challenge these antimicrobials \[[@b3-ophrp-10-0025]\]. Use of a macrolide, lincosamide and streptogramin B (MLS~B~) provides a narrow therapeutic range for treating Staphylococcal infections, but they are often considered as a substitute therapeutic regimen \[[@b4-ophrp-10-0025]\]. There are 3 different mechanisms of resistance to MLS~B~ including: (1) the *msr* gene which encodes active efflux pump; (2) the *lun* gene which encodes drug inactivation; and (3) ribosomal binding site alteration (by methylation and/or mutation within the 23s rRNA gene), encoded by *erm* cluster/genes (*ermA*, *ermB*, *ermC*, and *ermF*) among which, *ermA* and *ermC* are the main genes corresponding for resistance to MLS~B~ in Staphylococci, which can be constitutive or inducible. The *ermA* gene is situated on transposon Tn 554, which has insertion sites on the *S. aureus* chromosome \[[@b4-ophrp-10-0025]--[@b6-ophrp-10-0025]\]. The *ermB* gene is carried by transposon Tn551. The *ermC* gene has been shown to be on a 3.7-kb mobile genetic element on the plasmid.

Staphylococcal strains that are resistant to erythromycin, may be susceptible to clindamycin and give a D-shaped inhibition zone around the clindamycin disk with flattening towards erythromycin (an inducible MLS~B~ phenotype). Isolates resistant to both erythromycin and clindamycin with a spherical inhibition zone are known as having a constitutive resistance MLS~B~ (cMLS~B~) phenotype \[[@b7-ophrp-10-0025],[@b8-ophrp-10-0025]\]. Staphylococcal species showing resistance to erythromycin but sensitivity to clindamycin, gave a spherical district of inhibition around clindamycin and was categorized as having an MS (resistant to erythromycin and sensitive to clindamycin) phenotype \[[@b8-ophrp-10-0025]\]. The *msrA* gene codes for an ATP-dependent transporter that disseminates erythromycin and streptogramin B from the cell environment via energy, and has been recognized only in *Staphylococcus* species \[[@b9-ophrp-10-0025]\]. Also, to date, the mere efflux proteins corresponding for acquiring macrolide resistance described in *Staphylococcus* species, are ABC transporters encoded by plasmid-borne *msr* genes \[[@b5-ophrp-10-0025],[@b10-ophrp-10-0025]\]. The goal of the current study was phenotypic and genotypic investigation of resistance to MLS~B~, by a D-test and PCR for gene amplification among MRSA strains obtained from patients admitted to 3 teaching hospitals, in Tehran, Iran.

Material and Methods
====================

1. Clinical specimens and laboratory identification
---------------------------------------------------

In the descriptive cross-sectional study, 106 non-repetitive clinical isolates of MRSA were obtained over 15 months from May 2016 to July 2017 from individuals referred to 3 teaching hospitals (Shariati, Imam Khomeini, and Children's Medical Center), Tehran, Iran. All isolates were cultured on Mannitol Salt Agar (Mannitol plus 7.5% sodium chloride, Merck, Darmstadt, Germany) and incubated at 37°C for 24 hours. Recognition of all doubtful grown colonies was performed based on routine standard biochemical and microbiological tests. Strains were cultivated in Luria--Bertani broth (Merck, Darmstadt, Germany) plus 20% glycerol at −80°C for further uses.

2. Antibiotic susceptibility test
---------------------------------

In accordance with the Clinical and Laboratory Standards Institute (CLSI document M100, 28^th^ ed) recommendation \[[@b11-ophrp-10-0025]\], antimicrobial susceptibility assays were carried out on the Mueller-Hinton agar petri dishes (Merck, Darmstadt, Germany) using the disk agar diffusion technique for erythromycin (ERY; 15 μg), clindamycin (CC; 2 μg), gentamicin (GM; 10 μg), ciprofloxacin (CP; 5 μg), tetracycline (TE; 30 μg), ampicillin (AM; 20 μg), mupirocin (MUP; 5 μg), cefoxitin (FOX; 30 μg), rifampin (RA; 5μg), linezolid (LNZ; 30 μg) and trimethoprim-sulfamethoxazole (SXT; 5 μg) (MAST Diagnostics, Merseyside, UK). *S. aureus* ATCC 25923 was considered as a reference strain.

3. MIC E-test
-------------

Vancomycin (VA) MIC E-test strips (ranging from 0.016 to 256 μg/mL and interpretation criteria ≤ 2; S, 4--8; I and ≥ 16; R μg/mL, Liofilchem SRL, Roseto degli Abruzzi, Italy) were used in this study in concordance with the manufacturer's recommendations.

4. Determination of resistant phenotypes
----------------------------------------

The resistant phenotypes were identified through the double disk test with erythromycin (ERY; 15 μg), and clindamycin (C; 2 μg) disks applied 20 mm apart. After an incubation period of 24 hours at 35°C, a flattening inhibition zone adjacent to the ERY disk indicating an inducible type (D-shaped zone) of MLS~B~ resistance (IR), while resistance to both ERY and C was referred to as a constitutive type (CR). The absence of a D-shaped zone in ERY resistant and C-susceptible strains were construed as the M/MS~B~ efflux phenotype.

5. Molecular detection of resistance genes
------------------------------------------

Both M-PCR reactions were performed in a PCR instrument mastercycler gradient (Eppendorf, Hamburg, Germany) for detection of *ermA*, *ermB*, *ermC*, *msrA*, *msrB*, *ereA*, and *ereB* genes. Cellular DNA was obtained from MRSA isolates using a genomic DNA purification kit (Promega, Madison, Wisconsin, United States) according to the manufacturer's instructions. Appropriate primers for two M-PCR reactions, each targeting 4 different regions, and product size are listed in [Table 1](#t1-ophrp-10-0025){ref-type="table"}. The first set (S1) of M-PCR primers was designed to identify the *mecA*, *ermA* and *ereB* genes, and the second set (S2) for *ermB*, *ermC*, *msrA*, *msrB*, *ereA* genes. Both M-PCR reactions were done under the same conditions as follows: the total volume of the reaction mixture was 25 μL, including; DNA template (1 μL), 10× PCR buffer (1.8 μL), MgCl~2~ (50 mM; 0.7 μL), dNTPs (10 mM; 0.7 μL), forward/reverse primers (0.5 μL of each primer), *Taq* DNA polymerase (5 U/μL; 0.7 μL) (Amplicon Co., Denmark) and ddH~2~O (13.1 μL). The reaction conditions were started by a denaturation phase (95°C for 60 seconds), 33 cycles of denaturation for 45 seconds at 94°C, annealing for 30 seconds at 55°C and extension for 60 seconds at 72°C, and ended with a final extension phase (5 minutes at 72°C). PCR amplicons were examined by electrophoresis in 1.5% agarose gels (Sigma-Aldrich, United States) stained with ethidium bromide. Positive and negative controls were incorporated with each reaction.

6. Statistical analysis
-----------------------

Data were analyzed with Minitab 16 Statistical Software (Minitab Inc., State College, PA, USA). *p*-value and confidence intervals were \< 0.05 and 95%, respectively.

Results
=======

During a 15-month study period, a total of 106 FOX-resistant and MRSA isolates were obtained from various clinical samples including, wound (*n* = 37, 34.9%), pus (*n* = 25, 23.5%), blood (*n* = 21, 19.8%), bronchoalveolar lavage (*n* = 9, 8.2%), sputum (*n* = 6, 5.6%), intratracheal tube (*n* = 4, 3.7%), synovial fluid (*n* = 3, 2.8%) and cerebrospinal fluid (CSF) (*n* = 1, 0.9%). The frequency of MRSA isolates based on hospital ward distribution were internal medicine (*n* = 32), surgery (*n* = 23), pulmonary (*n* = 15), pediatrics (*n* = 12), NICU (*N* = 10), adult ICU (*n* = 8), orthopedics (*n* = 3), ENT (*n* = 2) and ophthalmology (*n* = 1). Each isolate was screened to detect the resistance to 12 antimicrobials. The resistance rates to ERY, CC, GM, CP, TE, AM, MUP, RA and SXT were 80.2%, 68.8%, 90.6%, 79.2%, 79.2%, 87.7%, 13.2%, 11.3%, and 66.9%, respectively. All isolates were susceptible to VA and LNZ. The highest susceptibility rates were related to MUP (86.7%) and RA (88.6%) ([Table 2](#t2-ophrp-10-0025){ref-type="table"}). All isolates that were resistant to FOX were considered as MRSA, phenotypically and confirmed by amplification of the *mecA-*gene by PCR. Furthermore, double disk diffusion test results revealed that 61 (57.5%) of the isolates were resistant to both CC and ERY of which, 48 (78.7%) strains had 4 different resistance phenotypes, of which 27 (56.2%) isolates had the resistant phenotype to cMLS~B~ (resistant to both ERY and CC), 11 (22.9%) isolates had the resistant phenotype to inducible resistance MLS~B~ (iMLS~B~; resistant to ERY and susceptible to CC), 8 (16.6%) isolates had the MS resistance phenotype (susceptible to ERY and resistant to CC) and finally, 2 (4.2%) isolates were susceptible to ERY and resistant to CC ([Figure 1](#f1-ophrp-10-0025){ref-type="fig"}). Of 11 isolates that had the iMLS~B~ resistant phenotype, *ermC* was positive in 81.8% (*n* = 9), *ermB* in 63.6% (*n* = 7), *ermA* in 54.5% (*n* = 6), and *ereA* in 18.2% (*n* = 2) of isolates, and out of these, *ermA/B/C* were co-present in 36.4% (*n* = 4). One iMLS~B~-resistant phenotype (9.1%) carried all of the *ermA/B/C* and *ereA* genes ([Table 3](#t3-ophrp-10-0025){ref-type="table"}). None of the isolates tested were negative for *ereB*, *msrA* and *msrB* genes. Therefore, 18.2% (*n* = 2) isolates with iMLS~B~ phenotypes did not have any tested genes.

In isolates with the cMLS~B~ phenotype, the prevalence of *ermA*, *ermB*, *ermC*, *msrA*, *msrB*, *ereA* and *ereB* were 7 (25.9%), 5 (18.5%), 12 (44.4%), 0 (0.0%), 0 (0.0%), 3 (11.1%) and 0 (0.0%), respectively. Of the 27 cMLS~B~ strains, 6 (22.2%), 4 (14.8%), 1 (3.7%) and 1 (3.7%) were positive for *ermA/ermC*, *ermA/ermB/ermC*, *ermA/ermB* and *ermC/ereA*, respectively. In the MS phenotype, *ermA*, *ermB* and *ermC* genes were found in 1 (12.5%), 0 (0.0%) and 3 (37.5%) strains, respectively. Other resistance genes were not found in this phenotype ([Figures 2](#f2-ophrp-10-0025){ref-type="fig"} and [3](#f3-ophrp-10-0025){ref-type="fig"}).

Discussion
==========

During the last decade, therapeutic drug failure has emerged due to abuse, overuse, and misappropriation of antimicrobial agents. Clindamycin is commonly used to treat skin/soft tissue infections, bone and joint infections because of its tolerability, price, low side effects, oral form, and good tissue penetration. There have been several reports on clindamycin or lincomycin therapy in severe infections due to Staphylococci with inducible MLS~B~ resistance \[[@b17-ophrp-10-0025]--[@b19-ophrp-10-0025]\]. Infections due to MRSA are significant causes of mortality and morbidity across the world \[[@b20-ophrp-10-0025]\]. The highest and lowest frequency of samples were collected in order from the wound and CSF. In addition, the highest antibiotic resistance rate was associated with GM (90.6%), and the lowest was RA (11.3%). All isolates were susceptible to VA and LNZ. Therefore, these antimicrobials are the most effective anti-Staphylococcal agent in our study. These data are similar to studies performed by Japoni et al \[[@b21-ophrp-10-0025]\], Ghosh et al \[[@b11-ophrp-10-0025]\] and Pournajaf et al \[[@b22-ophrp-10-0025]\].

The D-test is easy to perform and interpret, reproducible, and low-cost, but still not commonly used. D-test results of our study demonstrated that 61 (57.5%) isolates were sensitive to both ERY and CC; the frequency of cMLS~B~, iMLS~B~, and MS resistance phenotypes were found to be 27 (56.2%), 11 (22.9%), and 8 (16.6%), respectively. These results were similar to studies performed by Aktas et al \[[@b23-ophrp-10-0025]\] and Seifi et al \[[@b24-ophrp-10-0025]\], but in contrast to Ghanbari et al \[[@b13-ophrp-10-0025]\], Moosavian et al \[[@b25-ophrp-10-0025]\], Rahbar et al \[[@b26-ophrp-10-0025]\], and Jethwani et al \[[@b27-ophrp-10-0025]\]. These conflicts may be related to the prevalence of isolates with inducible resistance that can be dependent on geographic region, arbitrary use of antibiotics by patients, patient's age, species of bacteria, patient group, hospital wards, origin of samples and source of the strains like community or nosocomial. The frequency of inducible rates was also dissimilar from one hospital to another and even among patients \[[@b25-ophrp-10-0025],[@b28-ophrp-10-0025]\]. In the current study and in accordance with Mahesh et al \[[@b28-ophrp-10-0025]\], the frequency of the cMLS~B~ resistance phenotype was higher than iMLS~B~. In contrast, Reddy and Suresh found the frequency of the iMLS~B~ phenotype to be higher than the cMLS~B~ phenotype \[[@b29-ophrp-10-0025]\]. The treatment of Staphylococcal infection with resistant strains to iMLS~B~ can lead to the development of cMLS~B~ and failure in CC therapy, therefore detection of resistant strains to iMLS~B~ is more important than detecting other resistant phenotypes. Since, the occurrence of cMLS~B~, iMLS~B~, and MS phenotypes vary in different geographical areas, even among different hospitals, awareness of the regional frequency of MLS~B~ resistant isolates is important for microbiology laboratories to determine whether to perform the D-zone test routinely, or the reporting of all ERY-resistant *S. aureus* as CC-resistant \[[@b29-ophrp-10-0025]\]. As revealed in [Table 3](#t3-ophrp-10-0025){ref-type="table"}, the most widespread resistance gene was *ermC* (*n* = 24/46; 52.2%), followed by *ermA* (*n* = 14/46; 30.4%) and *ermB* (*n* = 12/46; 26.1%). Less common was ereA occurring in 10.8% (*n* = 5/46) of the ERY-resistant MRSA isolates tested. The *ereB*, *msrA* and *msrB* genes were not identified in any of the isolates. The prevalence of *ermC* and ermA in the present study were similar to the studies performed by Moosavian et al (*ermC*; 60.3% and *ermA*; 54.8%) \[[@b25-ophrp-10-0025]\] and Saderi et al (*ermC*; 41.1% and ermA; 17.7%) \[[@b30-ophrp-10-0025]\]. In concordance with our results, Cetin et al \[[@b4-ophrp-10-0025]\], Schmitz et al \[[@b31-ophrp-10-0025]\], and Westh et al \[[@b32-ophrp-10-0025]\] showed that *ermA* and *ermC* genes were associated with the majority of resistance to ERY among the MRSA. In contrast to Schmitz et al \[[@b31-ophrp-10-0025]\], the frequency of *ermA* and *ermC* genes was 88% and 47%, respectively. These results agree with Aktas et al \[[@b23-ophrp-10-0025]\] among the ERY-resistant MRSA collection, as *ermC* was predominant in strains expressing a cMLS~B~ (*n* = 12; 44.4%) and iMLS~B~ (*n* = 9; 81.8%) phenotype.

Out of the 106 isolates in our study, it was interesting that the *ereA* gene was present in all 5 (10.8%) strains with a resistant phenotype \[(cMLS~B~; 3 (11.1%), iMLS~B~; 2 (18.2%)\]. In contrast with our results, Schmitz et al \[[@b31-ophrp-10-0025]\] analyzed 851 clinical isolates of *S. aureus*, and showed that the *ereA* gene was not detected. In addition, the *ereB* gene was only found in an isolate with a cMLS~B~ phenotype (1.0%). We detected no MRSA with *msrA* and *msrB* resistance mechanisms. In contrast to our data, resistance to macrolides via efflux (*msrA*/*msrB* genes) was only found in MSSA (*n* = 14/358; 13%) by Schmitz et al \[[@b31-ophrp-10-0025]\], but Lina et al \[[@b33-ophrp-10-0025]\] showed the presence of *msrA*/*msrB* in both MSSA and MRSA isolates. A notable finding of the present study was that 1 (9.1%) isolate carried all of the *ermA/B/C* and *ereA* genes. The prevalence of *ermA/C* was 13.1% (*n* = 6) in our isolates. Nikbakht et al \[[@b34-ophrp-10-0025]\] showed the simultaneous presence of *ermA* and *ermC* in a significant number (*n* = 39/215, 18.14%) of their isolates. Since strains with inducible resistance may mutate and alter to constitutive resistance, laboratories must correctly identify C susceptibility using the D-zone method for eliminating inducible C resistance. CMLS~B~ was the most frequently encountered phenotypic pattern, with *erm* (C) being the most prevalent gene, and *erm* (A, C) the most frequent gene combination. This prevalence is perhaps due to the spread of distinctive clones (which carry *ermC* and *ermA* genes) in our area. In agreement with Siberry et al \[[@b35-ophrp-10-0025]\], the proportion of *S. aureus* with in vitro inducible clindamycin resistance (iCR) may differ by age group, region, and methicillin susceptibility. We emphasize that clinical laboratories should report in vitro iCR in *S. aureus* strains and that physicians should be alert of the potential for antimicrobial therapeutic failure when clindamycin is used to treat serious illnesses due to MRSA with in vitro iCR.
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###### 

The primer sequences used in the PCR reactions.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Reactions   Target genes                            Primer sequence (5′ → 3′)                 Amplicon size (bp)         References
  ----------- --------------------------------------- ----------------------------------------- -------------------------- --------------------------
  S1          *mecA*                                  F 5′-TCCAGATTACAACTTCACCAGG-3′\           310                        \[[@b12-ophrp-10-0025]\]
                                                      R 5′-CCACTTCATATCTTGTAACG-3′                                         

  *ermA*      F 5′-TATCTTATCGTTGAGAAGGGATT-3′\        139                                       \[[@b13-ophrp-10-0025]\]   
              R 5′-CTACACTTGGCTTAGGATGAAA-3′                                                                               

  *ereB*      F 5′-AGAAATGGAGGTTCATACTTACCA-3′\       546                                                                  
              R 5′-CATATAATCATCACCAATGGCA-3′                                                                               

                                                                                                                           

  S2          *ermB*                                  F 5′-CCGTTTACGAAATTGGAACAGGTAAAGGGC-3′\   359                        
                                                      R 5′-GAATCGAGACTTGAGTGTGC-3′                                         

  *ermC*      F 5′- ATCTTTGAAATCGGCTCAGG -3′\         295                                                                  
              R 5′- CAAACCCGTATTCCACGATT -3′                                                                               

  *msrA*      F 5′-TCCAATCATTGCACAAAATC-3′\           163                                       \[[@b14-ophrp-10-0025]\]   
              R 5′- AATTCCCTCTATTTGGTGGT-3′                                                                                

  *msrB*      F 5′-TATGATATCCATAATAATTATCCAATC-3′\    595                                       \[[@b15-ophrp-10-0025]\]   
              R 5′-AAGTTATATCATGAATAGATTGTCCTGTT-3′                                                                        

  *ereA*      F 5′- AACACCCTGAACCCAAGGGACG-3′\        420                                       \[[@b16-ophrp-10-0025]\]   
              R 5- 5′-CTTCACATCCGGATTCGCTCGA-3′                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Antibiotic resistance profile of the isolates tested.

      No. of antimicrobial resistance                                                                                                               
  --- --------------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  S   5 (4.7)                           9 (8.5)     11 (10.3)   25 (23.5)   16 (15.1)   0 (0.0)     18 (16.9)   92 (86.7)   32 (30.2)   94 (88.6)   106 (100)
                                                                                                                                                    
  I   5 (4.7)                           12 (11.3)   2 (1.8)     8 (7.5)     6 (5.6)     0 (0.0)     4 (3.7)     0 (0.0)     3 (2.8)     0 (0.0)     0 (0.0)
                                                                                                                                                    
  R   96 (90.6)                         85 (80.2)   93 (87.7)   73 (68.8)   84 (79.2)   106 (100)   84 (79.2)   14 (13.2)   71 (66.9)   12 (11.3)   0 (0.0)

Data are presented as *n* (%).

AM = ampicillin; CC = clindamycin; CP = ciprofloxacin; ERY = erythromycin; FOX = cefoxitin; GM = gentamicin; I = intermediate; LNZ = linezolid; MUP = mupirocin; R = resistant; RA = rifampin; S = susceptible; SXT = trimethoprim-sulfamethoxazole; TE = tetracycline.

###### 

Presence of the erm (A, B, C), msr (A, B) and ere (A, B) genes.

  Genes                            Types of resistant phenotypes   Total (*N* = 46)                          
  -------------------------------- ------------------------------- ------------------ ---------- ----------- -----------
  *erm* type genes                 *ermA*                          7 (25.9)           6 (54.5)   1 (12.5)    14 (30.4)
  *ermB*                           5 (18.5)                        7 (63.6)           0 (0.0)    12 (26.1)   
  *ermC*                           12 (44.4)                       9 (81.8)           3 (37.5)   24 (52.2)   
                                                                                                             
  *ere* type genes                 *ereA*                          3 (11.1)           2 (18.2)   0 (0.0)     5 (10.8)
  *ereB*                           0 (0.0)                         0 (0.0)            0 (0.0)    0 (0.0)     
                                                                                                             
  Combination of *erm* genes       *ermA+ ermB*                    1(3.7)             0 (0.0)    0 (0.0)     1 (2.2)
  *ermA+ermC*                      6 (22.2)                        0 (0.0)            0 (0.0)    6 (13.1)    
  *ermC+ermB*                      0 (0.0)                         0 (0.0)            0 (0.0)    0 (0.0)     
  *ermA+ermB+ermC*                 4 (14.8)                        4 (36.4)           0 (0.0)    8 (17.4)    
                                                                                                             
  Combination of *erm/ere* genes   *ermC+ereA*                     1 (3.7)            0 (0.0)    0 (0.0)     1 (2.2)
  *ermA/B/C +ereA*                 0 (0.0)                         1 (9.1)            0 (0.0)    1 (2.2)     
                                                                                                             
  PCR negative                     13 (48.1%)                      2 (18.2)           4 (50)     15 (24.6)   

Data are presented as *n* (%).

cMLS~B~ = constitutive resistance macrolide, lincosamide, and streptogramin B; iMLS~B~ = inducible resistance macrolide, lincosamide, and streptogramin B; MS = resistant to erythromycin and sensitive to clindamycin.
